Biden Announces $1.5B To Combat US Overdose Epidemic, Support Recovery
The White House announced $1.5 billion in funding to tackle opioid overdoses, sanctions against traffickers, and increased funding for law…
European Authority Backs AbbVie’s Crohn’s Disease Candidate
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval of AbbVie Inc’s (NYSE:ABBV)…
Top US Drugmakers Exploit US Patent System To Keep Generic Competition At Bay: Report
Citing the Initiative for Medicines, Access & Knowledge’s (I-MAK) report, Reuters said that several makers of top-selling drugs…
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
As part of President Joe Biden’s executive order to beef up U.S. biomanufacturing, the U.S. Department of Health and Human…
Biden Administration Pushes ‘Cancer Moonshot’ Initiative: Report
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it."
The President underscored his goal to cut the cancer death rate in the U.S. by at least 50% over the next 25 years.
This Is What Whales Are Betting On AbbVie
Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
What Are Whales Doing With AbbVie
A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie.
Looking at options history for AbbVie (NYSE:ABBV) we detected 16 strange trades.
AbbVie, Tesla, Financial Select Sector SPDR, iShares 20 Plus Year Treasury Bond And This Airline Are CNBC’s Final Trades
On CNBC’s “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management said that AbbVie Inc (NYSE: ABBV) has “come down from 175.” “It&rsqu
Tesla, AbbVie Are CNBC ‘Fast Money’ Mentions; Steve Weiss Is Shorting This ETF
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors.
Ironwood’s Constipation Drug Shows Efficacy In Pediatric Patients
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) announced topline data from a Phase 3 trial evaluating Linzess (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation.